Amitiza lubiprostone: Interim Phase III data

Interim data from a 48-week, open-label, Japanese Phase III safety trial in 209 CIC patients showed that 24 µg twice-daily oral lubiprostone was well tolerated with no severe adverse events reported. Additionally, lubiprostone improved all efficacy endpoints from baseline to week 24, including bowel movement frequency, straining, incomplete evacuation, stool consistency, abdominal bloating and abdominal discomfort. Lubiprostone also improved quality of life as measured by the IBS-QOL and SF-36 questionnaires from baseline to week 24. ...